BMS-986315

BIOLOGICAL2 trials

Sponsors

Bristol-Myers Squibb

Conditions

Advanced Solid TumorNSCLC

Phase 1

Study of BMS-986315 Alone and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid Tumors

CompletedNCT04349267

Bristol-Myers SquibbAdvanced Solid Tumor

Start: 2020-07-14End: 2024-08-22Updated: 2025-12-17

Phase 2

A Study of BMS-986315 and Nivolumab in Combination With Chemotherapy in Participants With First-line Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)

TerminatedNCT06094296

Bristol-Myers SquibbNSCLC

Start: 2023-11-27End: 2024-08-08Updated: 2025-04-16